Cytochrome P450 Mediated Bioactivation of Saracatinib
- 3 November 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (11), 1835-1842
- https://doi.org/10.1021/acs.chemrestox.6b00242
Abstract
Saracatinib is a highly selective Src kinase inhibitor against all Src kinase family members and has demonstrated anticancer effects in preclinical models. Unfortunately, it has shown multiple adverse effects during its clinical trials, along with time-dependent inhibition of P450 enzymes. The major objective of this study was to identify reactive metabolites of saracatinib in vitro and in vivo. Four oxidative metabolites (M1-M4) were detected in rat and human liver microsomal incubation systems after exposure to saracatinib. An ortho-quinone-derived reactive metabolite existing as a GSH conjugate (M5) was found in microsomes fortified with GSH as a trapping agent. The formation of the metabolites detected was NADPH dependent. Metabolites M2-M4 were also observed in bile and urine of rats given saracatinib, and M5 was only detected in bile. Inhibition and recombinant P450 enzyme incubation studies demonstrated that P450 3A4 was the primary enzyme responsible for the metabolic activation of saracatinib. The metabolism study facilitates the understanding of correlation between saracatinib-induced hepatotoxicity and bioactivation.Keywords
Funding Information
- National Natural Science Foundation of China (81373471, 81430086)
This publication has 16 references indexed in Scilit:
- A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s diseaseAlzheimer's Research & Therapy, 2015
- In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase InhibitorsDrug Metabolism and Disposition, 2014
- First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumoursInvestigational New Drugs, 2012
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer, 2011
- Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursInvestigational New Drugs, 2011
- Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530Molecular Oncology, 2009
- Assessment of the Metabolism and Intrinsic Reactivity of a Novel Catechol MetaboliteChemical Research in Toxicology, 2008
- Inhibition of Cytochrome P450 3A4 by a Pyrimidineimidazole: Evidence for Complex Heme InteractionsChemical Research in Toxicology, 2006
- N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase InhibitorJournal of Medicinal Chemistry, 2006
- Role of Quinones in ToxicologyChemical Research in Toxicology, 2000